EligibleTrials
Conditions › Psoriasis › NCT07486960

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

Recruiting · NCT07486960 · Interventional (participants receive a specific treatment) · Lead sponsor: Merck Sharp & Dohme LLC

View the official record on ClinicalTrials.gov →
Psoriasis

Interventions studied

PlaceboTulisokibart

What this trial is about

Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Who can take part

Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

50 locations listed across 12 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.